Roivant Sciences has launched a new biopharmaceutical firm called Cytovant Sciences which aims to offer cell therapy treatments to patients across Asia. The venture forms part of a collaboration with the Chinese drug manufacturer Sinovant Sciences, which was set up by Roivant last year to develop new medicines based on biomedical research and development. Cytovant has already agreed an exclusive licensing deal with the Medigene biotechnology firm German to use its T cell immunotherapy and will now commercialise products based on the technology in Greater China, South Korea and Japan.
Roivant Sciences has launched a new biopharmaceutical firm called Cytovant Sciences which aims to offer cell therapy treatments to patients across Asia. The venture forms part of a collaboration with the Chinese drug manufacturer Sinovant Sciences, which was set up by Roivant last year to develop new medicines based on biomedical research and development. Cytovant has already agreed an exclusive licensing deal with the German biotechnology firm Medigene to use its T cell immunotherapy and will now commercialise products based on the technology in Greater China, South Korea and Japan.